Theralase Technologies (CVE:TLT) Stock Price Up 10.9% - Time to Buy?

Key Points

• Theralase Technologies' share price jumped 10.9% on Friday to C$0.26, with trading volume of about 505,131 shares, roughly a 96% increase versus the average.
• The company has a market cap of C$74.41 million and a negative P/E of -15.00, with a current ratio of 0.83, quick ratio of 3.40 and a debt-to-equity ratio of 29.26, suggesting mixed liquidity and leverage metrics.
• Theralase is a clinical-stage pharmaceutical developer focused on light-activated photodynamic compounds and patented super-pulsed laser technology for treating cancers, infections and chronic pain.

Theralase Technologies Inc. (CVE:TLT - )'s share price rose 10.9% during trading on Friday . The company traded as high as C$0.26 and last traded at C$0.26. Approximately 505,131 shares were traded during mid-day trading, an increase of 96% from the average daily volume of 257,414 shares. The stock had previously closed at C$0.23.

Theralase Technologies Stock Up 17.4%

The firm has a market cap of C$74.41 million, a price-to-earnings ratio of -15.00 and a beta of -0.33. The company has a current ratio of 0.83, a quick ratio of 3.40 and a debt-to-equity ratio of 29.26. The firm has a 50 day moving average price of C$0.29 and a 200-day moving average price of C$0.24.

Theralase Technologies Company Profile

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.